Carysil Files ICRA Monitoring Agency Report for QIP Fund Utilisation for Quarter Ended March 31, 2026
Carysil Limited submitted the ICRA Limited Monitoring Agency report for Q4 FY2026 to the stock exchanges on May 11, 2026, covering QIP fund utilisation for the quarter ended March 31, 2026. The QIP, with a revised net proceeds figure of INR 121.65 crore, recorded total utilisation of INR 87.86 crore by the end of the quarter, leaving an unutilised balance of INR 33.79 crore. ICRA confirmed no material deviation from the objects of the issue, with the Board having approved a timeline extension for capital expenditure utilisation to March 31, 2027. Unutilised funds are deployed in fixed deposits with HDFC Bank and a cash credit account with Citi Bank, with total market value of INR 34.99 crore at the end of the quarter.

*this image is generated using AI for illustrative purposes only.
Carysil Limited has filed the Monitoring Agency (MA) report prepared by ICRA Limited with the stock exchanges for the quarter ended March 31, 2026, in compliance with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report pertains to the utilisation of funds raised through the company's Qualified Institutions Placement (QIP) and was submitted on May 11, 2026. ICRA Limited was appointed as the Monitoring Agency pursuant to an agreement dated July 01, 2024.
Issue Details
The QIP was open from July 01, 2024, to July 03, 2024, involving the issuance of equity shares with a total issue size of INR 125.00 crore. The net proceeds, after deducting issue-related expenses (IRE) of INR 3.30 crore as per the prospectus, were initially stated at INR 121.70 crore. These net proceeds were subsequently revised to INR 121.65 crore owing to issue-related expenses being higher by INR 0.05 crore as on December 31, 2025.
| Parameter: | Details |
|---|---|
| Issue Period: | July 01, 2024 – July 03, 2024 |
| Type of Issue: | QIP |
| Type of Securities: | Equity Shares |
| Issue Size: | INR 125.00 crore |
| Net Proceeds (as per prospectus): | INR 121.70 crore |
| Revised Net Proceeds: | INR 121.65 crore |
| Revision Reason: | IRE higher by INR 0.05 crore |
Fund Utilisation Progress
ICRA confirmed that the utilisation of issuance proceeds is in line with the objects of the issue, with no material deviation observed. The report also noted that the means of finance for the disclosed objects has not changed, all government and statutory approvals have been obtained, and no major deviation was observed over earlier monitoring agency reports. The following table summarises the progress in utilisation of QIP proceeds as at March 31, 2026.
| Item Head: | Proposed Amount [Rs. Crore] | Utilised at Beginning of Quarter [Rs. Crore] | Utilised During Quarter [Rs. Crore] | Utilised at End of Quarter [Rs. Crore] | Unutilised Amount [Rs. Crore] |
|---|---|---|---|---|---|
| Capital Expenditure (machines, equipment & moulds): | 62.50 | 23.37 | 5.34 | 28.71 | 33.79 |
| Working Capital Requirements: | 31.25 | 31.25 | – | 31.25 | NIL |
| General Corporate Purposes: | 27.90 | 27.90 | – | 27.90 | NIL |
| Total: | 121.65 | 82.52 | 5.34 | 87.86 | 33.79 |
Cost of Objects
The original and revised costs for each object of the issue are detailed below. The revision in the general corporate purpose allocation is attributable to the increase in issue-related expenses by INR 0.05 crore.
| Item Head: | Original Cost [Rs. Crore] | Revised Cost [Rs. Crore] |
|---|---|---|
| Capital Expenditure (machines, equipment & moulds): | 62.50 | Not Applicable |
| Working Capital Requirements: | 31.25 | Not Applicable |
| General Corporate Purposes: | 27.95 | 27.90 |
| Total: | 121.70 | 121.65 |
Deployment of Unutilised Proceeds
The unutilised balance of INR 33.79 crore has been deployed across 13 fixed deposits with HDFC Bank and a balance in the cash credit account with Citi Bank. All fixed deposits carry a return on investment of 6.25% or 6.35% per annum, with maturity dates ranging from August 24, 2026, to February 25, 2027. The total market value of deployed unutilised proceeds as at the end of the quarter stood at INR 34.99 crore, inclusive of earnings of INR 1.20 crore. The cash credit account with Citi Bank held an unutilised balance of INR 1.29 crore as on March 31, 2026, reflecting total available funds of INR 6.63 crore (comprising an opening balance of INR 1.63 crore and INR 5.00 crore transferred upon closure of a fixed deposit), of which INR 5.34 crore was utilised up to March 31, 2026.
General Corporate Purpose Utilisation
The total general corporate purpose amount of INR 27.90 crore has been fully utilised across the following heads:
| Item Head: | Amount [Rs. Crore] | Quarter of Utilisation |
|---|---|---|
| Advertising & Publicity Expenses: | 2.22 | Q3 FY2025 |
| Acrysil USA Loan Payment: | 2.81 | Q4 FY2025 |
| Raising Funds – Right Issue CSL: | 4.25 | Q4 FY2025 |
| Supplier's Payment: | 18.20 | Q4 FY2025 |
| Sales Promotion Expenses: | 0.42 | Q4 FY2025 |
| Total: | 27.90 |
Timeline Extension for Capital Expenditure
ICRA noted that the Board of Directors of Carysil Limited, at their meeting No. 07/2025-26 held on March 20, 2026, passed a resolution approving the extension of the timeline for utilisation of QIP proceeds earmarked for capital expenditure from March 31, 2026, to March 31, 2027. Accordingly, the remaining INR 33.79 crore is expected to be utilised by the fiscal year ended March 31, 2027. The working capital requirements and general corporate purposes allocations were completed on schedule. The report was prepared by Parul Goyal Narang, Vice President & Head – Process Excellence at ICRA Limited, and submitted to Reena Shah, Company Secretary and Compliance Officer of Carysil Limited.
Historical Stock Returns for CARYSIL
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.54% | -3.86% | +8.43% | -11.74% | +41.30% | +193.36% |
How will the deployment of the remaining INR 33.79 crore in capital expenditure on machines, equipment, and moulds impact Carysil's production capacity and revenue growth by FY2027?
Given the timeline extension for capex utilisation to March 2027, what risks could arise if macroeconomic conditions or supply chain disruptions further delay equipment procurement?
How might the INR 2.81 crore loan repayment to Acrysil USA and the INR 4.25 crore rights issue funding for CSL reflect on Carysil's broader international expansion and subsidiary financing strategy?


































